Californian vaccine firm Vaxcyte (Nasdaq: PCVX) has announced positive results from a Phase II study of VAX-24, its broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate.
Data was also presented from the full six-month safety assessment and prespecified pooled immunogenicity analyses from both the Phase II study in adults aged 65 and older, and the prior Phase I/II study in adults aged 18 to 64.
"We look forward to meeting with regulators and advancing VAX-24 into a pivotal Phase III study"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze